CIMZIA (Certolizumab Pegol) is effective in the treatment of Crohn's Disease patients with open fistulas

被引：0
|
作者：
Schreiber, S. [1 ]
Lawranc, I [2 ]
Thomsen, O. [3 ]
Hanauer, S. [4 ]
Bloomfield, R. [5 ]
Sandborn, W. [6 ]
机构：
[1] Univ Kiel, Hosp Gen Internal Med, Kiel, Germany
[2] Univ Western Australia, Fremantle Hosp, Fremantle, WA, Australia
[3] Univ Copenhagen, Herlev Hosp, DK-2730 Herlev, Denmark
[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[5] UCB Pharma, Slough, Berks, England
[6] Mayo Clin, Rochester, MN USA
来源：
INFLAMMATORY BOWEL DISEASES | 2008年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 50 条
  • [41] CERTOLIZUMAB PEGOL IN PATIENTS WITH CROHN'S DISEASE: A LONG TERM UPDATE OF COMPASSIONATE USE
    Mocciaro, F.
    Renna, S.
    Orlando, A.
    Olivo, M.
    Sinagra, E.
    Cottone, M.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S189 - S189
  • [42] Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice
    Knyazev, O., V
    Kagramanova, A., V
    Lishchinskaya, A. A.
    Samsonova, N. G.
    Orlova, N., V
    Rogozina, V. A.
    Parfenov, A., I
    TERAPEVTICHESKII ARKHIV, 2018, 90 (06) : 74 - 80
  • [43] New biologics in the management of Crohn's disease: focus on certolizumab pegol
    Colombo, Elisabetta
    Bossa, Fabrizio
    Latiano, Anna
    Palmieri, Orazio
    Andriulli, Angelo
    Annese, Vito
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2009, 2 : 61 - 68
  • [44] Certolizumab pegol for maintenance of medically induced remission in Crohn's disease
    Okabayashi, Shinji
    Yamazaki, Hajime
    Yamamoto, Ryohei
    Anan, Keisuke
    Matsuoka, Katsuyoshi
    Kobayashi, Taku
    Shinzaki, Shinichiro
    Honzawa, Yusuke
    Kataoka, Yuki
    Tsujimoto, Yasushi
    Watanabe, Norio
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (06):
  • [45] Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease
    Blonski, Wojciech
    Buchner, Anna M.
    Lichtenstein, Gary R.
    CLINICAL MEDICINE INSIGHTS-GASTROENTEROLOGY, 2012, 5 : 11 - 21
  • [46] Certolizumab Pegol Plasma Concentration and Clinical Remission in Crohn's Disease
    Sandborn, William J.
    Hanauer, Stephen B.
    Pierre-Louis, Bosny
    Lichtenstein, Gary R.
    GASTROENTEROLOGY, 2012, 142 (05) : S563 - S563
  • [47] Efficacy and safety of certolizumab pegol for Crohn's disease in clinical practice
    Moon, W.
    Pestana, L.
    Becker, B.
    Loftus, E. V., Jr.
    Hanson, K. A.
    Bruining, D. H.
    Tremaine, W. J.
    Kane, S. V.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (04) : 428 - 440
  • [48] Assessment of the Safety of Certolizumab Pegol for the Treatment of Crohn's Disease at a Single North American Center
    Lee, Scott
    Ko, Cynthia
    Wheat, Chelle
    Harper, Jason
    Cullinan, Cory
    Etter, Scott
    Pulling, Michele
    Sinanan, Mika
    Wahbeh, Ghassan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S471 - S472
  • [49] Risk-benefit Assessment of Adalimumab and Certolizumab Pegol as Induction Treatment for Crohn's Disease
    Colombel, Jean-Frederic
    Panaccione, R.
    Robinson, Anne
    Thakkar, Roopal
    Huang, Bidan
    Pollack, Paul
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S466 - S466
  • [50] Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870)
    Dinesen, Lotte
    Travis, Simon
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2007, 2 (01): : 39 - 47
12345